(184) Novel lipid nanoparticles for pulmonary delivery of circRNA vaccines

Introduction: The mucosal immune system, constituting the largest component of the overall immune system, has evolved to provide protection at sites of primary infectious threat, notably the mucosa1. Despite this, most studies on COVID-19 have focused exclusively on systemic cell-mediated immunity, with limited progress in inducing mucosal immunity2. We design a pulmonary surfactant (PS) modified lipid nanoparticles (PS-LNPs) for the pulmonary delivery of circular RNA (circRNA) vaccine to elicit respiratory mucosal immunity with potential applications in the prophylaxis of respiratory infectious diseases.